A non-randomized, open-label, multi-center, Phase I/II study of PI3K inhibitor copanlisib in pediatric patients with relapsed/refractory solid tumors or lymphoma (BAY 80-6946 /19176)
This Study is
No Longer Enrolling
Details
Age
Child to Adult
Type of Study
Treatment
Locations
Childrens Hospital Colorado
Study ID
Protocol Number: 17-1495
More information available at ClinicalTrials.gov: NCT03458728
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers